- Policy
- Improvement of reimbursement standards for Prolia is needed
- by Lee, Hye-Kyung Oct 20, 2020 09:15am
- The government has announced that it will comprehensively review the reimbursement standards for osteoporosis treatments such as 'Prolia (Denosumab)'. The MOHW expanded Prolia, which was used as a second-line treatment for osteoporosis last year, as a first-line treatment, and recognized reimbursement even if continuous administration is n
- Policy
- President Moon Jae-in visited the SK Bio Research Institute
- by Lee, Jeong-Hwan Oct 19, 2020 06:19am
- President Moon Jae-in visited the COVID-19 vaccine/treatment development site on the 15th and promised to become a 'strong supporter' that helps the final development while encouraging researchers to check the development status and participate in clinical trials. President Moon urged domestic COVID-19 vaccine and treatment developers to d
- Policy
- KHIDI “COVID-19 drug grants checks feasibility first"
- by Lee, Jeong-Hwan Oct 19, 2020 06:19am
- The Korea Health Industry Development Institute (KHIDI) noted the contingency budget on seeking the COVID-19 treatment and vaccine can only be provided for drugs submitted an application with realistic anticipation to result in treatment performance. At the National Assembly Health and Welfare Committee audit session on Oct. 15, Presiden
- Policy
- CKD-516, clinical approval for combined use of 'Imfinzi'
- by Lee, Tak-Sun Oct 19, 2020 06:19am
- Chong Kun Dang's new anticancer drug candidate'CKD-516' is in a clinical trial to determine the effectiveness of the combination of immunotherapy for cancer ‘Imfinzi’ (Durvalumab, AZ). At the American Cancer Society (AACR) 2019 that was held last year, the possibility of combined use of immuno-cancer drugs was highlighted, and then the
- Policy
- Immune checkpoint inhibitors require many considerations
- by Lee, Tak-Sun Oct 17, 2020 06:37am
- The MOHW showed a cautious attitude toward the expansion of the benefits of the primary lung cancer treatment for immune checkpoint inhibitors. This is because the patient's treatment opportunities expand, but enormous insurance finances may be required. The MOHW made this statement in a written answer to a question related to Jongseong
- Policy
- Pirespa·Kanarb are the targets of drug price negotiations
- by Lee, Hye-Kyung Oct 17, 2020 06:37am
- Ildong's 'Pirespa 200mg (Pirfenidone)' and Boryung's 'Kanarb 30, 60, 120mg (Fimasartan potassium)' and other drugs with increased usage were targeted for the price-volume agreement negotiation system monitoring. Roche Korea's 'Zelboraf 240mg (Vemurafenib)', Pfizer Korea's 'Inlyta1·5mg (Axitinib)', and Ipsen's 'Dysport (Clostridium botul
- Policy
- Atozet latecomer CKD Atoezy wins approval without PMS
- by Lee, Tak-Sun Oct 17, 2020 06:36am
- Chong Kun Dang has reportedly received the South Korean health authority’s approval on a follow-on drug of MSD’s dyslipidemia treatment Atozet. The approval preceded Atozet’s post-marketing surveillance (PMS) end date on Jan. 22 next year by three months, putting the latecomer on an advantageous position. However, the estimated l
- Policy
- 13,000 Allergan breast implant recipient data missing
- by Lee, Hye-Kyung Oct 17, 2020 06:36am
- Apparently, the information on 13,000 patients who received Allergan’s textured breast implant has not been fully surveyed, yet. In August last year, South Korea’s Ministry of Food and Drug Safety (MFDS) has ordered healthcare providers to halt using the implant and recalled the products as a patient, who received the implant, has been dia
- Policy
- Insurance benefits for Vizimpro·Ferinject were passed
- by Lee, Hye-Kyung Oct 15, 2020 06:05am
- Pfizer Pharmaceutical Korea's non-small cell lung cancer treatment 'Vizimpro (Dacomitinib)' was recognized as reimbursement drug. Eisai Korea's Equfina 50mg (Safinamide mesylate), an adjuvant therapy for Parkinson's disease patients, and JW Pharmaceutical's iron formulation,'Ferinject inj (Ferric hydroxide carboxymaltose complex)', also pass
- Policy
- The number of generics in Korea is more than 10 times higher
- by Lee, Jeong-Hwan Oct 14, 2020 06:24am
- It is pointed out that the number of generic drugs with the same active ingredient licensed in Korea is “more than 10 times higher” in foreign countries such as the United States and France. This is the result of comparing the top five items with the largest number of domestic marketing generics with overseas cases. In particular, it was
